Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1–7) mas receptor expression associated with its PPAR-γ agonist action

References

• Lasaridis AN, Sarafidis PA. Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials? Am J Hyper 2003;16:689–697.
   PubMed Web of Science ®Google Scholar
• Molitch ME, DeFronzo RA, Franz MJ. Nephropathy in diabetes. Diabetes Care 2004;27:79–83.
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346: 1080–1084.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288–296.
   PubMed Web of Science ®Google Scholar
• Lane TA, Lamkin GE, Wancewicz EV. Protein kinase C inhibitors block the enhanced expression of intercellular adhesion molecule-1 of endothelial cells activated by interleukin-1, lipopolysaccharide and tumor necrosis factor. Biochem Biophys Res Commun 1990;103:172–177.
   Google Scholar
• Ibrahim HN, Hostetter TH. Diabetic nephropathy. J Am Soc Nephrol 1997;8:487–493.
   PubMed Web of Science ®Google Scholar
• Wolf G, Ziyadeh FN. The role of Angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Diseases 1997;29:153–163.
   PubMed Web of Science ®Google Scholar
• Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000;15:61–63.
   PubMed Web of Science ®Google Scholar
• Luft FC. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2002;11:59–66.
   PubMed Web of Science ®Google Scholar
• Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 upregulation in mesangial cells and in diabetic kidney. Kidney Int 2005;67:1762–1771.
   PubMed Web of Science ®Google Scholar
• Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003;14:221–226.
   PubMed Web of Science ®Google Scholar
• Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 2008;233:4–11.
   PubMed Web of Science ®Google Scholar
• Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008;57:460–469.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehner H, Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H. Combination treatment of angiotensin-II receptor blocker and angiotensin converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003;361:117–124.
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005;20:2670–2680.
   PubMed Web of Science ®Google Scholar
• Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002;283:F861–F875.
   PubMed Web of Science ®Google Scholar
• Satoh M, Kashihara N, Yamasaki Y. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2001;12:317–325.
   PubMed Web of Science ®Google Scholar
• Seeland U, Schäffer A, Selejan S, Hohl M, Reil JC, Müller P, Rosenkranz S, Böhm M. Effects of ATI- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice. Eur J Clin Invest 2009;39:851–859.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zou R, Liu X, Jian J, Huang Q, He Y, Li M, Wang S, Zhou J, Ma D, Xu G. Telmisartan but not valsartan inhibits TGF-beta mediated accumulation of extracellular matrix via activation of PPARgamma. E Pub 2008;28:543–548.
   Google Scholar
• Gurusamy N, Watanabe K, Ma M, Zhang S, Muslin AJ, Kodama M, Aizawa Y. Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK. Biochem Biophys Res Commun 2004;320:773–780.
   PubMed Web of Science ®Google Scholar
• Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76–85.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009;60:378–381.
   Web of Science ®Google Scholar
• Cosentino F, Hishikawa K, Katusic ZS. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997;96:25.
   PubMed Web of Science ®Google Scholar
• Thandavarayan RA, Watanabe K, Sari FR, Ma M, Lakshmanan AP, Giridharan VV, Gurusamy N, Nishida H, Konishi T, Zhang S, Muslin AJ, Kodama M, Aizawa Y. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38a mitogen-activated protein kinase mice. Free Radic Biol Med 2010;49:1422–1431.
   PubMed Web of Science ®Google Scholar
• Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens 2008;26:973–980.
   PubMed Web of Science ®Google Scholar
• Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33238–33243.
   PubMed Web of Science ®Google Scholar
• Singh R, Singh A, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 2005;288:F1183–F1190.
   PubMed Web of Science ®Google Scholar
• McCollum LT, Gallagher PE, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces COX-2 in cardiac fibroblasts. Hypertension 2006;48:79.
   Web of Science ®Google Scholar
• Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003;41:392–397.
   PubMed Web of Science ®Google Scholar
• Betul K, Melek O, Matem T, Omer U, Fatma KD, Itır Y, Ekrem E. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochemica 2002;104:123–130.
   PubMed Web of Science ®Google Scholar
• Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 2003;46:1428–1437.
   PubMed Web of Science ®Google Scholar
• Geiszt M, Lekstrom K, Witta J, Leto TL. Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. J Biol Chem 2003;278:20006–20012.
   PubMed Web of Science ®Google Scholar
• Cui XL, Douglas JG. Arachidonic acid activates c-jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells. Proc Natl Acad Sci USA 1997; 94:3771–3776.
   PubMed Web of Science ®Google Scholar
• Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol 1995;5:1483–1491.
   PubMed Web of Science ®Google Scholar
• Lasségue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol 2003; 285:R277–R297.
   PubMed Web of Science ®Google Scholar
• El-Benna J, My-Chan Dang P, Gougerot-Pocidalo M-A, Marie J-C, Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med 2009;41:217–225.
   PubMed Web of Science ®Google Scholar
• Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186–194.
   PubMed Web of Science ®Google Scholar
• Wendt MC, Daiber A, Kleschyov AL, Mülsch A, Sydow K, Schulz E, Chen K, Keaney JF Jr, Lass gue B, Walter U, Griendling KK, Münzel T. Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. Free Radiac Biol Med 2005;39:381–391.
   PubMed Web of Science ®Google Scholar
• Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54:775–784.
   PubMed Web of Science ®Google Scholar
• Block K, Ricono JM, Lee DY, Bhandari B, Choudhury GG, Abboud HE, Gorin Y. Arachidonic acid dependent activation of a p22(phox)-based NAD(P)H oxidase mediates angiotensin II-induced mesangial cell protein syntheses and fibronectin expression via Akt/PKB. Antioxid Redox Signal 2006;8:1497–1508.
   PubMed Web of Science ®Google Scholar
• Pearse DD, Tian RX, Nigro J, Lorgulescu JB, Puzis L, Jaimes EA. Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. Am J Physiol Renal Physiol 2008;294: F1094–F1100.
   Web of Science ®Google Scholar
• Zhao W, Chen SS, Chen Y, Ahokas RA, Sun Y. Kidney fibrosis in hypertensive rats: role of oxidative stress. Am J Nephrol 2008;28:548–554.
   PubMed Web of Science ®Google Scholar
• Lodha S, Dani D, Mehta R, Bhaskaran M, Reddy K, Ding G, Singhal PC. Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med 2002;8:830–840.
   PubMed Web of Science ®Google Scholar
• Aradaillou R, Chansel D, Chatziantoniou C, Dussaule JC. Mesangial AT1 receptors: expression, signaling, and regulation. J Am Soc Nephrol 1999;10:S40–S46.
   Web of Science ®Google Scholar
• Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCOMCBN, the American Diabetes Association and the German Diabetes Society. Diabete Metab Res Rev 2001;17:189–212.
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993–1002.
   PubMed Web of Science ®Google Scholar
• Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K. Telmisartan down regulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006;72:184–190.
   PubMed Web of Science ®Google Scholar
• Dhaunsi GS, Yousif MH, Akhtar S, Chappell MC, Diz DI, Benter IF. Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol 2010;638:108–114.
   PubMed Web of Science ®Google Scholar
• Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003;108:2805–2811.
   PubMed Web of Science ®Google Scholar
• Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thulé PM, Sutliff RL, Hart CM. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul Pharmacol 2007; 46:456–462.
   PubMed Web of Science ®Google Scholar
• Prasad B, Ravi N, Asma K, James RS, Adam WC. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009;5:129–140.
   PubMedGoogle Scholar
• Dunlop ME, Muggli EE. Small heat shock protein alteration provide a mechanism to reduce mesangial cell contractility in diabetes and oxidative stress. Kidney Int 2000;57:464–475.
   PubMed Web of Science ®Google Scholar
• Kang S, Adler SG, Janine L, Natarajan R. p38 MAPK and MAPK 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int 2001;60:543–552.
   PubMed Web of Science ®Google Scholar
• Reddy MA, Adler SG, Kim Y, Lanting L, Rossi J, Kang S, Nadler JL, Shahed A, Natarajan R. Interaction of MAPK and 12-lipooxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol 2002; 283:F985–F994.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Kasseri Z, Patel MP, Chappell MC, Buany J, Backx PH, Tsushima RG, Scholey JW, Khokha R, Penninger JM. Angiotensin II oxidative stress and inflammation mediate the age dependent cardiomyopathy in ACE2 null mice. Cardiovascular Res 2007;75:29–39.
   PubMed Web of Science ®Google Scholar
• Zdychova J, Komers K. Emerging role of akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res 2005;54:1–16.
   PubMed Web of Science ®Google Scholar